Table 3 Medical consultation and health problems 40 to 56 days after boost COVID-19 vaccination
ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA | |
|---|---|---|---|
(n = 462) | (n = 1638) | (n = 5004) | |
Medical consultation, thereof… | 69 (14.9%) | 287 (17.5%) | 796 (15.9%) |
Outpatient | |||
Yes | 61 (88.4%) | 248 (86.4%) | 667 (83.8%) |
Not yet, but planned | 6 (8.7%) | 36 (12.5%) | 117 (14.7%) |
No | 2 (2.9%) | 3 (1.0%) | 12 (1.5%) |
Inpatient/Clinic | |||
Yes | 13 (18.8%) | 21 (7.3%) | 85 (10.7%) |
Not yet, but planned | 1 (1.4%) | 2 (0.7%) | 9 (1.1%) |
No | 55 (79.7%) | 264 (92%) | 702 (88.2%) |
Pre-existing conditions | |||
Yes | 11 (15.9%) | 40 (13.9%) | 103 (12.9%) |
Partially | 22 (31.9%) | 95 (33.1%) | 291 (36.6%) |
No | 36 (52.2%) | 152 (53%) | 402 (50.5%) |
Suspected association to vaccination | |||
Yes | 3 (4.3%) | 16 (5.6%) | 36 (4.5%) |
Partially | 10 (14.5%) | 60 (20.9%) | 171 (21.5%) |
No | 56 (81.2%) | 211 (73.5%) | 589 (74.0%) |
Perceived affection by the health problems | |||
Strongly disagree | 6 (8.7%) | 24 (8.4%) | 72 (9%) |
Disagree | 7 (10.1%) | 38 (13.2%) | 88 (11.1%) |
Agree | 21 (30.4%) | 108 (37.6%) | 326 (41%) |
Strongly agree | 35 (50.7%) | 117 (40.8%) | 310 (38.9%) |
Perceived long-term consequences by the health problems | |||
Strongly disagree | 20 (29.0%) | 98 (34.1%) | 237 (29.8%) |
Disagree | 28 (40.6%) | 104 (36.2%) | 256 (32.2%) |
Agree | 15 (21.7%) | 54 (18.8%) | 212 (26.6%) |
Strongly agree | 6 (8.7%) | 31 (10.8%) | 91 (11.4%) |
ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA | |
|---|---|---|---|
(n = 462) | (n = 1638) | (n = 5004) | |
Health problems leading to medical consultation, thereof… | |||
Musculoskeletal disorders | 35 (7.6%) | 123 (7.5%) | 321 (6.4%) |
Muscle weakness | 5 (1.1%) | 14 (0.9%) | 44 (0.9%) |
Back pain | 14 (3%) | 60 (3.7%) | 157 (3.1%) |
Pain in extremities | 15 (3.2%) | 57 (3.5%) | 150 (3.0%) |
Joint swelling | 5 (1.1%) | 19 (1.2%) | 42 (0.8%) |
Arthritis | 8 (1.7%) | 13 (0.8%) | 57 (1.1%) |
Subsultus | 0 (0%) | 14 (0.9%) | 33 (0.7%) |
Mobility disorder | 7 (1.5%) | 15 (0.9%) | 61 (1.2%) |
General symptoms | 25 (5.4%) | 108 (6.6%) | 357 (7.1%) |
Flu-like symptoms | 5 (1.1%) | 36 (2.2%) | 105 (2.1%) |
Dyspnoea | 4 (0.9%) | 10 (0.6%) | 55 (1.1%) |
Fever | 2 (0.4%) | 19 (1.2%) | 43 (0.9%) |
Nausea/vomiting | 2 (0.4%) | 18 (1.1%) | 71 (1.4%) |
Abdominal pain | 1 (0.2%) | 29 (1.8%) | 84 (1.7%) |
Fatigue | 13 (2.8%) | 51 (3.1%) | 174 (3.5%) |
Weakness | 14 (3.0%) | 52 (3.2%) | 156 (3.1%) |
Malaise | 11 (2.4%) | 45 (2.7%) | 122 (2.4%) |
Neurological disorders | 26 (5.6%) | 102 (6.2%) | 268 (5.4%) |
Headache | 12 (2.6%) | 60 (3.7%) | 160 (3.2%) |
Dizziness | 11 (2.4%) | 39 (2.4%) | 121 (2.4%) |
Paraesthesia | 8 (1.7%) | 28 (1.7%) | 63 (1.3%) |
Unconsciousness | 0 (0%) | 1 (0.1%) | 6 (0.1%) |
Neuralgia | 6 (1.3%) | 30 (1.8%) | 79 (1.6%) |
Seizure | 1 (0.2%) | 1 (0.1%) | 7 (0.1%) |
Minor stroke | 0 (0%) | 0 (0%) | 4 (0.1%) |
Paralysis | 0 (0%) | 2 (0.1%) | 4 (0.1%) |
Multiple sclerosis | 0 (0%) | 2 (0.1%) | 5 (0.1%) |
Cardiovascular disorders/Risk factors | 11 (2.4%) | 41 (2.5%) | 128 (2.6%) |
Diabetes | 5 (1.1%) | 4 (0.2%) | 19 (0.4%) |
Palpitations | 3 (0.6%) | 20 (1.2%) | 63 (1.3%) |
Chest pain | 2 (0.4%) | 16 (1.0%) | 53 (1.1%) |
Heart attack | 0 (0%) | 1 (0.1%) | 2 (0%) |
Myocarditis | 0 (0%) | 1 (0.1%) | 4 (0.1%) |
Vasculitis | 1 (0.2%) | 3 (0.2%) | 3 (0.1%) |
Pulmonary embolism | 0 (0%) | 0 (0%) | 1 (0%) |
Blood clot | 1 (0.2%) | 3 (0.2%) | 4 (0.1%) |
Coagulation disorder | 2 (0.4%) | 3 (0.2%) | 6 (0.1%) |
Unsolicited health problems | 38 (8.2%) | 162 (9.9%) | 389 (7.8%) |